Pacira BioSciences (NASDAQ:PCRX) Announces Earnings Results

Pacira BioSciences (NASDAQ:PCRX) issued its earnings results on Tuesday. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.08, FiscalAI reports. Pacira BioSciences had a return on equity of 10.24% and a net margin of 0.70%.The company had revenue of $192.40 million for the quarter, compared to analyst estimates of $191.06 million. During the same period in the prior year, the firm posted $0.74 EPS. The business’s revenue was up 6.2% compared to the same quarter last year.

Here are the key takeaways from Pacira BioSciences’ conference call:

• Second-quarter revenue increased 6% to $192.4 million, led by EXPAREL sales growth of 3% to $147.8 million, ZILRETTA growth of 4%, and iovera° growth of 21%.
• EXPAREL continued gaining share despite softness in deferrable elective soft-tissue procedures. Expanded commercial-payer coverage, including UnitedHealthcare, brings separate reimbursement to more than 150 million covered lives, supporting further adoption in outpatient settings.
• Pacira lowered its 2026 total revenue guidance to $735 million-$760 million from $745 million-$770 million, primarily reflecting the iovera° divestiture; consolidated non-GAAP gross margin also declined to 78% from 82% a year ago.
• The company expects several pipeline catalysts by year-end, including data from ZILRETTA’s shoulder osteoarthritis study, iovera°’s spasticity study, and Part A of the PCRX-201 Phase II trial. Pacira also reported $251 million in cash and investments before receiving the $70 million upfront payment from Zimmer Biomet.
• Pacira completed the iovera° divestiture to Zimmer Biomet for up to $140 million, filed EXPAREL for approval in South Korea through LG Chem with potential revenue beginning in 2027, and said it remains open to additional partnerships while focusing capital on near-term, risk-managed growth opportunities.

Pacira BioSciences Stock Up 2.6%

NASDAQ PCRX traded up $0.70 during trading on Tuesday, hitting $27.62. 1,130,089 shares of the company traded hands, compared to its average volume of 548,910. Pacira BioSciences has a 12 month low of $18.80 and a 12 month high of $27.66. The business has a fifty day simple moving average of $24.60 and a 200 day simple moving average of $23.32. The company has a current ratio of 4.73, a quick ratio of 3.35 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $1.09 billion, a P/E ratio of 16.93 and a beta of 0.27.

Analyst Upgrades and Downgrades

PCRX has been the subject of several research reports. Zacks Research upgraded Pacira BioSciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 7th. Needham & Company LLC increased their price objective on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, May 1st. HC Wainwright reaffirmed a “buy” rating and set a $38.00 price objective on shares of Pacira BioSciences in a research report on Wednesday, July 1st. Royal Bank Of Canada lifted their target price on shares of Pacira BioSciences from $22.00 to $24.00 and gave the company a “sector perform” rating in a research note on Friday, May 1st. Finally, Weiss Ratings raised shares of Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, May 20th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $29.40.

Insider Activity

In other news, SVP Lauren Riker sold 6,115 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $23.50, for a total transaction of $143,702.50. Following the completion of the sale, the senior vice president owned 62,284 shares in the company, valued at approximately $1,463,674. This represents a 8.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Pacira BioSciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. grew its holdings in Pacira BioSciences by 5,900.0% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company’s stock valued at $39,000 after purchasing an additional 1,475 shares during the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Pacira BioSciences during the 4th quarter worth $48,000. Global Retirement Partners LLC boosted its holdings in shares of Pacira BioSciences by 479.4% during the 4th quarter. Global Retirement Partners LLC now owns 2,028 shares of the company’s stock worth $52,000 after buying an additional 1,678 shares during the period. Strs Ohio bought a new stake in shares of Pacira BioSciences during the 1st quarter worth $75,000. Finally, iSAM Funds UK Ltd acquired a new position in Pacira BioSciences in the 3rd quarter valued at $80,000. 99.73% of the stock is currently owned by institutional investors and hedge funds.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.